The primary objective of this study was to determine the current rate of lead fracture during temporary percutaneous peripheral nerve stimulator (PNS) lead removal at the Mayo Clinic Rochester Division of Pain Medicine.
Materials and Methods
A retrospective review of electronic medical records was performed for patients implanted with a temporary percutaneous PNS device between January 1, 2018, and December 31, 2020. Patients were included if they underwent temporary percutaneous PNS system implant, with planned lead removal at 60 days. Data collection included date of implant, diagnosis, peripheral nerve target(s), number of leads, and lead tip status at the time of removal (intact vs fractured).
Fifty patients underwent a total of 80 temporary percutaneous PNS leads placed during the time frame analyzed. Of the 80 temporary percutaneous PNS leads implanted, there were five lead fractures at the time of intentional lead removal.
This retrospective review of 50 patients with 80 temporary percutaneous PNS leads implanted for chronic peripheral neuropathic pain resulted in a 6.25% rate of retained lead fragment at the time of lead removal by the provider at the end of 60-day treatment. This fracture and retention rate is consistent with previous published retrospective data on PNS, which has shown a 3% to 21% lead fracture rate during intentional lead removal.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A review of the bioelectronic implications of stimulation of the peripheral nervous system for chronic pain conditions.Bioelectron Med. 2020; 6: 9https://doi.org/10.1186/s42234-020-00045-5
- Sprint Therapeutics. SPRcare reimbursement.(. Accessed February 16, 2022.)
- Spinal cord and peripheral nerve stimulation for painful disorders.Adv Anesth. 2019; 37: 163-186https://doi.org/10.1016/j.aan.2019.08.010
- Subcutaneous target stimulation (STS) in chronic noncancer pain: a nationwide retrospective study.Pain Pract. 2010; 10: 279-286
- Peripheral nerve field stimulation for chronic pain: 100 cases and review of the literature.Pain Med. 2011; 12: 1395-1405
- Peripheral subcutaneous field stimulation for the treatment of spinal cord injury at-level pain: case report, literature review, and 5-year follow-up.Heliyon. 2020; 6e04515https://doi.org/10.1016/j.heliyon.2020.e04515
- Percutaneous peripheral nerve stimulation (neuromodulation) for postoperative pain: a randomized, sham-controlled pilot study.Anesthesiology. 2021; 135: 95-110https://doi.org/10.1097/ALN.0000000000003776
- Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial.Reg Anesth Pain Med. 2019; 44: 637-645
- A feasibility study of percutaneous peripheral nerve stimulation for the treatment of postoperative pain following total knee arthroplasty.Neuromodulation. 2019; 22: 653-660https://doi.org/10.1111/ner.12790
- In vitro magnetic resonance imaging evaluation of fragmented, open-coil, percutaneous peripheral nerve stimulation leads.Neuromodulation. 2018; 21: 276-283https://doi.org/10.1111/ner.12705
- Ultrasound-guided percutaneous peripheral nerve stimulation: neuromodulation of the suprascapular nerve and brachial plexus for postoperative analgesia following ambulatory rotator cuff repair. A proof-of-concept study.Reg Anesth Pain Med. 2019; 44: 310-318https://doi.org/10.1136/rapm-2018-100121
Published online: February 25, 2022
Accepted: January 8, 2022
Received in revised form: December 26, 2021
Received: October 7, 2021
Source(s) of financial support: The authors reported no funding sources.
Conflict of Interest: The authors reported no conflict of interest.
© 2022 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.